These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 37943967)

  • 21. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
    De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
    Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
    Shaefer CF; Kushner P; Aguilar R
    Postgrad Med; 2015; 127(8):818-26. PubMed ID: 26371721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats.
    Chelikani PK; Haver AC; Reidelberger RD
    Am J Physiol Regul Integr Comp Physiol; 2005 Jun; 288(6):R1695-706. PubMed ID: 15718384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.
    Little TJ; Pilichiewicz AN; Russo A; Phillips L; Jones KL; Nauck MA; Wishart J; Horowitz M; Feinle-Bisset C
    J Clin Endocrinol Metab; 2006 May; 91(5):1916-23. PubMed ID: 16492694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacotherapy for Type 2 Diabetes Mellitus: What's Up and Coming in the Glucagon-Like Peptide-1 (GLP-1) Pipeline?
    Elder MJ; Ashjian EJ
    J Pharm Pract; 2023 Apr; 36(2):418-428. PubMed ID: 34620002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide.
    Sherwin M; Hamburger J; Katz D; DeMaria S
    Can J Anaesth; 2023 Aug; 70(8):1300-1306. PubMed ID: 37466909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GLP-1 regulates gastroduodenal motility involving cholinergic pathways.
    Schirra J; Nicolaus M; Woerle HJ; Struckmeier C; Katschinski M; Göke B
    Neurogastroenterol Motil; 2009 Jun; 21(6):609-18, e21-2. PubMed ID: 19220754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.
    Jørgensen NB; Dirksen C; Bojsen-Møller KN; Jacobsen SH; Worm D; Hansen DL; Kristiansen VB; Naver L; Madsbad S; Holst JJ
    Diabetes; 2013 Sep; 62(9):3044-52. PubMed ID: 23649520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exendin(9-39)NH
    Gasbjerg LS; Bari EJ; Christensen M; Knop FK
    Diabetes Obes Metab; 2021 Nov; 23(11):2419-2436. PubMed ID: 34351033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.
    Salehi M; Vahl TP; D'Alessio DA
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4909-16. PubMed ID: 18827000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
    Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
    Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.
    Urva S; O'Farrell L; Du Y; Loh MT; Hemmingway A; Qu H; Alsina-Fernandez J; Haupt A; Milicevic Z; Coskun T
    Diabetes Obes Metab; 2023 Sep; 25(9):2784-2788. PubMed ID: 37311727
    [No Abstract]   [Full Text] [Related]  

  • 33. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.
    Schirra J; Nicolaus M; Roggel R; Katschinski M; Storr M; Woerle HJ; Göke B
    Gut; 2006 Feb; 55(2):243-51. PubMed ID: 15985560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
    Meier JJ; Kemmeries G; Holst JJ; Nauck MA
    Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nitrergic contribution to gastric relaxation induced by glucagon-like peptide-1 (GLP-1) in healthy adults.
    Andrews CN; Bharucha AE; Camilleri M; Low PA; Seide B; Burton D; Baxter K; Zinsmeister AR
    Am J Physiol Gastrointest Liver Physiol; 2007 May; 292(5):G1359-65. PubMed ID: 17290009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
    Maida A; Lovshin JA; Baggio LL; Drucker DJ
    Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
    Rosenstock J; Blonde L; Aroda VR; Frias J; Souhami E; Ji C; Niemoeller E; Del Prato S
    Diabetes Obes Metab; 2021 Jun; 23(6):1331-1341. PubMed ID: 33565209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gastric and intestinal satiation in obese and normal weight healthy people.
    Meyer-Gerspach AC; Wölnerhanssen B; Beglinger B; Nessenius F; Napitupulu M; Schulte FH; Steinert RE; Beglinger C
    Physiol Behav; 2014 Apr; 129():265-71. PubMed ID: 24582673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans.
    Delgado-Aros S; Kim DY; Burton DD; Thomforde GM; Stephens D; Brinkmann BH; Vella A; Camilleri M
    Am J Physiol Gastrointest Liver Physiol; 2002 Mar; 282(3):G424-31. PubMed ID: 11841992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.